Alendronate, a
nitrogen containing
bisphosphonate (BPP), when given p.o., decreases the transmucosal potential difference by direct irritating action, resulting in non-hemorrhagic lesions in both the corpus and antrum of fasted rats, and after re-feeding produces large
ulcers in the antrum with increased vascular permeability and submucosal
edema. The pathogenesis of these
ulcers may be explained by the impairment of the mucosal anti-oxidative system and does not involve
acid digestion as well as a deficiency of
prostaglandins (PGs).
Alendronate, although does not affect
cyclooxygenase/
PGE(2) production in the ulcerated mucosa, but impairs the healing of
gastric ulcers in rats, and this effect may be related to the down-regulation of
vascular endothelial growth factor and
basic fibroblast growth factor (bFGF), the important
growth factors for the vascularization/granulation as well as the suppression of the stimulatory action of
epidermal growth factor on the epithelial proliferation/migration.
Rebamipide, a mucosal protective and antiulcer drug, does not affect the direct irritating action of
alendronate in the gastric mucosa but prevents the
alendronate-induced
antral ulceration, probably due to anti-oxidative and anti-inflammatory actions. In addition, this agent also antagonizes the healing impairment action of
alendronate by counteracting the down-regulation of bFGF expression in the ulcerated mucosa. It is assumed that
rebamipide is a promising drug that can be used as a prophylactic against the adverse effects of BPPs in the stomach.